Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2022

View Archived Issues

ProfoundBio presents novel ADCs for cancer treatment

University of California discloses new PRMT8 inhibitors

Vertex Pharmaceuticals patents CFTR potentiators

Dana-Farber Cancer Institute discloses new HER2 inhibitors

Merck & Co. presents DGAT-2 inhibitors

Idorsia Pharmaceuticals patents LGALS3 inhibitors

AC-0027875, a gamma-secretase modulator for the treatment of AD

To escape radiation, tumor cells reversibly damage their DNA

Discovery of pyrrolo-pyridine benzamide derivative with promising antitumor efficacy in vivo

Apramycin shows efficacy in models of Mycobacterium abscessus infections

Discovery of novel D4R antagonist with favorable in vivo PK profile

ProMIS reports potential therapeutic approaches for ALS and nominates lead candidate

Series A financing supports Kelonia's development of in vivo gene delivery technology

HanAll advances novel immuno-oncology antibodies HL-187/HL-186

Chimera Bioengineering advances preclinical testing of CAR-T therapy CBIO-007 for solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...